(Boursier.com) — GeNeuro announces its results for the first half of 2022
and provides an update on its developments with a confirmed solid financial situation and high visibility:
The cash position is 11 ME. Funding for activities is assured until Q4 2023.
Start of the Phase 2 clinical trial evaluating temelimab in patients with “long COVID”:
-The personalized medicine trial will evaluate temelimab as a disease-modifying therapy in patients with long COVID with severe neurological and psychiatric symptoms who are positive for the presence of the pathogenic protein W-ENV in their blood
New data on the link between HERV-K ENV and Amyotrophic Lateral Sclerosis:
-Publication in the journal Annals of Neurology of two studies demonstrating the neurotoxic role of the envelope protein of the human endogenous retrovirus HERV-K in patients with Charcot’s disease and the relevance of targeted therapy with the new specific antibody from GeNeuro
©2022 Boursier.com